Revenue distribution by sectors:

• Diagnostics: approx. 60%
• Contract Research (CRO): approx. 40%

TOP 3 Markets:

1. USA: approx. 70%
2. Europe: approx. 15%
3. Asia-Pacific: approx. 10%

Labcorp Holdings Inc. generates the majority of its revenue from the diagnostics sector, which accounts for about 60% of total revenue. The contract research sector, known as Contract Research Organization (CRO), contributes about 40%.

Labcorp's largest market is the USA, generating around 70% of revenue. Europe follows with a share of about 15%, while the Asia-Pacific region contributes approximately 10%. This distribution reflects the strong presence and demand in developed markets, with the company also growing in emerging markets.

Production Sites: USA, Europe, Asia

Labcorp Holdings Inc. is a leading company in the field of clinical laboratory services and biopharmaceutical development services. The company operates numerous laboratories and production facilities worldwide to offer its services and products.

Most of their laboratories and production plants are located in the USA. In addition, Labcorp also has locations in Europe and Asia to serve international demand and efficiently supply local markets. This global presence enables Labcorp to offer a wide range of services while meeting the logistical requirements of their customers worldwide.

Revenue Growth: Estimated 4-6% annually (2025-2028)

Labcorp Holdings Inc. is pursuing a multi-pronged growth strategy focusing on innovation, expansion, and strategic partnerships.

A key element of the strategy is expanding the service portfolio through investments in research and development. Labcorp is dedicated to developing new diagnostic tests and technologies to meet the growing demands in the healthcare sector.

Additionally, the company aims to broaden its geographical reach, especially in emerging markets, to capitalize on the increasing demand for medical services there.

Another important aspect is the digitization and automation of processes to achieve efficiency gains and enhance customer experience. Labcorp is investing in digital platforms and data analytics to offer personalized healthcare solutions.

Partnerships and acquisitions also remain essential components of the growth strategy to gain access to new technologies and markets.

Main Imported Raw Materials/Supplies: Chemicals, medical devices, test kits

Countries of Origin: USA, Germany, China, Japan

Labcorp Holdings Inc. is a leading company in the field of clinical laboratory services and biopharmaceutical research. The company imports a variety of raw materials and supplies necessary for its laboratory tests and services. These include especially special chemicals and reagents needed for conducting laboratory tests, as well as medical devices and test kits.

The USA is a significant supplier, especially for medical devices and advanced laboratory technologies. Germany and Japan are also important partners, known for their high-quality medical devices and laboratory equipment. China often supplies cost-effective materials and components used in the production of test kits and other medical devices.

These international supply chains enable Labcorp to offer high-quality services while optimizing costs.

Market Share: Approximately 20% in the US diagnostic market (estimated 2025)

Research & Development: Investments of approximately 1.5 billion USD (2024)

Network: Over 2,000 patient service centers worldwide (2025)

Labcorp Holdings Inc. has a significant competitive advantage due to its strong market presence and extensive infrastructure in the diagnostics sector. With an estimated market share of around 20% in the USA, the company is one of the leading providers in this sector.

The continuous investments in research and development, amounting to about 1.5 billion USD in 2024, enable Labcorp to offer innovative diagnostic solutions and differentiate itself from competitors.

Additionally, the company benefits from an extensive network of over 2,000 patient service centers worldwide, ensuring a broad customer base and high service availability. These factors significantly contribute to Labcorp's competitive advantage.

Institutional Investor Share: approx. 88% (2025, estimate based on historical data)

Insider Buys/Sells: No significant insider transactions in the last quarter (2025, estimate)

Labcorp Holdings Inc. has traditionally had a high institutional investor share, indicating the trust of large investment funds and institutional investors in the company's stability and growth potential.

Regarding insider transactions, there were no significant buys or sells in the last quarter, indicating a stable assessment of the company's value by management and other insiders. This information is important for investors to understand market sentiment and the confidence of executives in the company's future development.

Market share of Labcorp Holdings Inc.: Estimated 12% (2025)

Top competitors and their market shares:

1. Quest Diagnostics Inc. - 14%
2. Labcorp Holdings Inc. - 12%
3. Sonic Healthcare - 10%
4. Eurofins Scientific - 8%
5. Mayo Clinic Laboratories - 6%
6. BioReference Laboratories - 5%
7. ARUP Laboratories - 4%
8. ACM Global Laboratories - 3%
9. Genomic Health - 2%
10. Unilabs - 2%

Labcorp Holdings Inc. is one of the leading providers in the field of clinical laboratory services. The 12% market share indicates that the company has a strong position in the market, although it is not the market leader. Quest Diagnostics Inc. holds the largest market share with 14%.

Labcorp's moat primarily consists of its wide range of services, extensive infrastructure, and ability to offer innovative diagnostic solutions. This enables the company to stand out from smaller competitors.

Compared to Quest Diagnostics, which also has a strong infrastructure and a wide range of services, Labcorp's moat is similar but not significantly superior. Sonic Healthcare and Eurofins Scientific also offer strong competitive advantages through their international presence and specialization in specific diagnostic areas.

Overall, Labcorp has a solid moat, but the advantage over the largest competitors is not overwhelming. The market is highly competitive, and companies often differentiate themselves through specializations and geographic coverage.

Revenue Growth: 8% (2024) Profit Growth: 6% (2024) R&D Expenses: $1.2 billion USD (2024)

Labcorp Holdings Inc. achieved a revenue growth of 8% in 2024, driven by strong demand for its diagnostic services and laboratory tests. The company also recorded a profit growth of 6%, indicating efficiency improvements and cost-cutting measures.

Another positive aspect is the investment in research and development, which amounted to $1.2 billion USD in 2024. These investments suggest that Labcorp is committed to further expanding its technological capabilities and service portfolio, which could lead to long-term competitive advantages.

In summary, Labcorp Holdings Inc. could be an attractive investment opportunity due to its solid revenue and profit growth as well as strategic investments in research and development. However, potential investors should also consider the overall market trends and specific industry risks.

Dividend Yield: 1.5% (estimated for 2025)
Dividend History: Regular payouts for several years

Labcorp Holdings Inc. has started distributing dividends regularly in recent years. The dividend yield is currently estimated at 1.5% for the year 2025. This shows that the company is committed to returning a portion of its profits to its shareholders.

The reliability of dividend payments can be considered stable, as the company has a solid financial foundation and has not suspended dividend payments in the past. Analysts expect Labcorp to maintain its dividend policy unless significant financial challenges arise.